Use of interleukin-15

Inactive Publication Date: 2007-06-14
GROOTEN JOHAN ADRIAAN MARC +2
View PDF5 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017] Other possible indications of this approach are individuals showing hyporesponsiveness towards pathogens or vaccins, or suffering from a chronic infection or from a generally weakened immune condition. As we assume that the action of IL-15 becomes even more important

Problems solved by technology

Normally, the disappearance of these growth factors—a consequence of the ending of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of interleukin-15
  • Use of interleukin-15
  • Use of interleukin-15

Examples

Experimental program
Comparison scheme
Effect test

example

1. Materials and Methods

1.1. CD4+ T Cell Clone

[0048] The influenza A / H3 haemagglutinin (HA)-specific and H-2b restricted CD4+ murine T cell clone T-HA was developed in this laboratory by an initial immunisation of C57BI / 6 mice with 100 μg / ml bromelain cleaved haemagglutinin (BHA) and 0.5 mg / ml adjuvant (Ribi, Immunochem Research Inc., Hamilton, Mont., USA) and a second immunisation with 32 μg / ml BHA three weeks later.

[0049] 5 days after this boost immunisation lymph nodes were isolated and 3.107 cells were stimulated in vitro with 0.5 μg / ml BHA in 25 cm2 culture flasks (Nunclon, Nunc, Roskilde, Denmark). On day 4 10 U / ml mouse IL-2 (from PMA stimulated EL4.IL-2 cells) was added to the cultures.

[0050] After 2 additional biweekly restimulations with 0.5 μg / ml BHA and APC, a pool of optimally HA-reactive T-lymphocytes was obtained. These T-HA cells were maintained long term in vitro by biweekly restimulation in 25 cm2 culture flasks with 10 ng / ml BHA and 7×107 syngeneic spleen ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the use of IL-15 or active variants thereof and/or IL-15 activity enhancing compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system, such as manipulating viability and/or responsiveness of said memory cells. The IL-15 activity enhancing compound is for example lipopolysaccharide (LPS). The invention further relates to the use of IL-15 inhibiting or eliminating compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system. Such inhibiting or eliminating compounds are for example anti-IL-15 antibodies, anti-IL-15Rα antibodies, fragments of these antibodies, e.g. the Fab or F(ab′)2 fragment, soluble IL-15Rα, fusion proteins consisting of soluble IL-15Rα, and Fc fragment, compounds, e.g. peptides, binding and/or inhibiting functional IL-15 receptor, IL-15 antisense oligonucleotides.

Description

RELATED APPLICATIONS [0001] The present application is a continuation of U.S. application Ser. No. 10 / 045,185, filed Oct. 18, 2001, which is a divisional application of U.S. Ser. No. 09 / 380,049, filed Aug. 23, 1999, now U.S. Pat. No. 6,344,192, which is the U.S. national phase under 35 U.S.C. § 371 of International Application No. PCT / EP98 / 00127, filed Feb. 23, 1998. All of the above applications are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] The present invention relates to a new use of Interleukin-15 (IL-15). The invention further relates to pharmaceutical preparations, containing IL-15 itself, IL-15 stimulating compounds or IL-15 inhibiting and / or eliminating compounds. [0003] The cytokine interleukin-15 (IL-15) was originally identified in culture supernatants of the simian kidney epithelial cell line CV-1 / EBNA and the T cell leukemia cell line HuT-102 (Grabstein et al., 1994; Burton et al., 1994; Bamford et al., 1994). The IL-15 cDNA sequence encodes a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/70C12Q1/68A61K38/20C12N5/02
CPCA61K38/1793A61K38/2086Y10S930/141Y10S930/14
Inventor GROOTEN, JOHAN ADRIAAN MARCDOOMS, HANS PETER RAFFIERS, WALTER CHARLES
Owner GROOTEN JOHAN ADRIAAN MARC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap